JS 120
Alternative Names: JS-120Latest Information Update: 13 Jan 2023
At a glance
- Originator Shanghai Junshi Biosciences
- Developer Shanghai Junshi Biosciences; Wigen Biomedicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Jan 2023 Preclinical trials in Cancer in China (unspecified route) before January 2023 (Shanghai Junshi Biosciences pipeline, January 2023)
- 31 Mar 2022 Junshi Biosciences and Wigen Biomedicine collaborate to develop small molecule therapeutic for the treatment of cancer
- 31 Mar 2022 Early research in Cancer in China (unspecified route)